{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:42:01Z","timestamp":1775688121961,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Depress Anxiety"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1002\/da.22525","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T16:27:05Z","timestamp":1463070425000},"page":"728-736","source":"Crossref","is-referenced-by-count":33,"title":["AUGMENTATION STRATEGIES FOR TREATMENT-RESISTANT ANXIETY DISORDERS: A SYSTEMATIC REVIEW AND META-ANALYSIS"],"prefix":"10.1155","volume":"33","author":[{"given":"Beth","family":"Patterson","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioural Neurosciences; McMaster University; Hamilton Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Van\u00a0Ameringen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioural Neurosciences; McMaster University; Hamilton Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,12]]},"reference":[{"key":"10.1002\/da.22525-BIB0001|da22525-cit-0001","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1002\/da.22525-BIB0002|da22525-cit-0002","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions' of DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1002\/da.22525-BIB0003|da22525-cit-0003","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.mp.4001852","article-title":"Treatment-resistant anxiety disorders","volume":"11","author":"Bystritsky","year":"2006","journal-title":"Mol Psychiatry"},{"key":"10.1002\/da.22525-BIB0004|da22525-cit-0004","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"10.1002\/da.22525-BIB0005|da22525-cit-0005","first-page":"005473","article-title":"Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders","volume":"4","author":"Ipser","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/da.22525-BIB0006|da22525-cit-0006","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jad.2010.08.025","article-title":"CBT for pharmacotherapy non-remitters-a systematic review of a next-step strategy","volume":"129","author":"Rodrigues","year":"2011","journal-title":"J Affect Disord"},{"key":"10.1002\/da.22525-BIB0007|da22525-cit-0007","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","article-title":"Social phobia","volume":"22","author":"Liebowitz","year":"1987","journal-title":"Mod Probl Pharmacopsychiatry"},{"key":"10.1002\/da.22525-BIB0008|da22525-cit-0008","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"62","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"10.1002\/da.22525-BIB0009|da22525-cit-0009","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0022-3956(01)00028-0","article-title":"Reliability and validity of the panic disorder severity scale: replication and extension","volume":"35","author":"Shear","year":"2001","journal-title":"J Psychiatr Res"},{"key":"10.1002\/da.22525-BIB0010|da22525-cit-0010","volume-title":"The Anxiety Disease","author":"Sheehan","year":"1983"},{"key":"10.1002\/da.22525-BIB0011|da22525-cit-0011","volume-title":"Cochrane Reviewers\u2019 Handbook","volume":"5","author":"Higgins","year":"2008"},{"key":"10.1002\/da.22525-BIB0012|da22525-cit-0012","volume-title":"Review manager (RevMan)","author":"The Cochrane Collaboration","year":"2012"},{"key":"10.1002\/da.22525-BIB0013|da22525-cit-0013","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1002\/da.22525-BIB0014|da22525-cit-0014","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e328341bb4a","article-title":"Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review","volume":"26","author":"Samuel","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/da.22525-BIB0015|da22525-cit-0015","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1592\/phco.30.9.942","article-title":"Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder","volume":"30","author":"Lorenz","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1002\/da.22525-BIB0016|da22525-cit-0016","unstructured":"Van Ameringen M http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00182455?term=treatment+resistant+generalized+anxiety+disorder&recr=Open&rank=2"},{"key":"10.1002\/da.22525-BIB0017|da22525-cit-0017","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopsych.2005.07.005","article-title":"Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study","volume":"59","author":"Pollack","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1002\/da.22525-BIB0018|da22525-cit-0018","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/YIC.0b013e3283457d73","article-title":"Augmentative quetiapine in partial\/nonresponders with generalized anxiety disorder: a randomized, placebo-controlled study","volume":"26","author":"Altamura","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/da.22525-BIB0019|da22525-cit-0019","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/YIC.0b013e328350b133","article-title":"Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment","volume":"27","author":"Rickels","year":"2012","journal-title":"Int J Clin Psychopharm"},{"key":"10.1002\/da.22525-BIB0020|da22525-cit-0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1176\/appi.ajp.2013.12101353","article-title":"A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder","volume":"171","author":"Pollack","year":"2014","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22525-BIB0021|da22525-cit-0021","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.4088\/JCP.08m04485blu","article-title":"Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial","volume":"70","author":"Simon","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22525-BIB0022|da22525-cit-0022","unstructured":"Goddard AW Mahmud W Medlock C Shin YW 2012"},{"key":"10.1002\/da.22525-BIB0023|da22525-cit-0023","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1176\/appi.ajp.158.10.1725","article-title":"Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study","volume":"158","author":"Stein","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.22525-BIB0024|da22525-cit-0024","unstructured":"Kinrys G Bianco R Oltramari A 2013"},{"key":"10.1002\/da.22525-BIB0025|da22525-cit-0025","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.4088\/JCP.v66n1016","article-title":"Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study","volume":"66","author":"Brawman-Mintzer","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22525-BIB0026|da22525-cit-0026","first-page":"41","article-title":"Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial","volume":"40","author":"Pandina","year":"2007","journal-title":"Psychopharmacol Bull"},{"key":"10.1002\/da.22525-BIB0027|da22525-cit-0027","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00213-008-1087-x","article-title":"Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings","volume":"197","author":"Simon","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/da.22525-BIB0028|da22525-cit-0028","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JCP.0b013e3181d21951","article-title":"Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study","volume":"30","author":"Lohoff","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.22525-BIB0029|da22525-cit-0029","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hup.1165","article-title":"Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo","volume":"26","author":"Schutters","year":"2011","journal-title":"Hum Psychopharmacol"},{"key":"10.1002\/da.22525-BIB0030|da22525-cit-0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00004714-200010000-00011","article-title":"Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial","volume":"20","author":"Hirschmann","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.22525-BIB0031|da22525-cit-0031","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4088\/JCP.v63n0904","article-title":"A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone","volume":"63","author":"Kampman","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.22525-BIB0032|da22525-cit-0032","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. rating the quality of evidence - study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1002\/da.22525-BIB0033|da22525-cit-0033","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1002\/da.22525-BIB0034|da22525-cit-0034","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S1461145712000740","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"16","author":"Dold","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1002\/da.22525-BIB0035|da22525-cit-0035","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1517\/14656566.7.11.1515","article-title":"After the failure of citalopram for depression, what next?","volume":"7","author":"Doggrell","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1002\/da.22525-BIB0036|da22525-cit-0036","article-title":"The Canadian anxiety guidelines initiative group on behalf of the Anxiety Disorders Association of Canada\/Association Canadienne des trouble anxieux and McGill University","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psychiatry"}],"container-title":["Depression and Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fda.22525","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fda.22525","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/da.22525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:04:38Z","timestamp":1671541478000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/da.22525"}},"subtitle":["Review: Augmentation in Refractory Anxiety Disorders"],"short-title":[],"issued":{"date-parts":[[2016,5,12]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"URL":"https:\/\/doi.org\/10.1002\/da.22525","archive":["Portico"],"relation":{},"ISSN":["1091-4269"],"issn-type":[{"value":"1091-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5,12]]}}}